In a 2023 cost-effectiveness analysis, use of GFAP and UCH-L1 biomarkers reduced CT use by 325 scans per 1,000 patients compared to universal CT screening, by identifying low-risk cases suitable for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results